[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"developmental-delay-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:developmental-delay-disorder":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,81,108,135,204,241,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100595883","genotypephenotype-correlation-of-morc2-mutations-100595883",false,"NCT07038239","Genotype\u002FPhenotype Correlation of MORC2 Mutations","Deciphering MORC2 Genotype\u002FPhenotype Correlation to Improve Patient Diagnostic","PhenoMORC2","Inclusion Criteria:\n\n* Presence of a mutation in the MORC2 gene, identified during an evaluation for peripheral neuropathy or intellectual disability\n* Patient has undergone electromyography (EMG) or is able to undergo EMG during the inclusion visit\n* Affiliation with the national health insurance system\n* Informed consent from the patient if an adult, or from parents\u002Flegal guardians if the patient is a minor\n\nExclusion Criteria:\n\n* Presence of another mutation responsible for peripheral neuropathy or intellectual disability\n* Refusal to undergo biological sample collection\n* Regulatory exclusion criteria:\n* Pregnant, postpartum, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals not affiliated with a social security system or not benefiting from an equivalent health coverage scheme","ALL","4 Years",{"count":20,"type":21},45,"ESTIMATED","OBSERVATIONAL","The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy.\n\nDifferent mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN.\n\nMORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.",[25,26,27,28,29],"Charcot Marie Tooth Disease","DIFGAN","Developmental Delay (Disorder)","Impaired Growth","Dysmorphic Facies and Axonal Neuropathy",[31,26,32,33,34,35,36,37],"Charcot-Marie-Tooth","Human silencing hub complex","genotype-phenotype correlation","MORC2","DNA dalage repair","transcriptional modulation","EPIGENETIC","RECRUITING","2026-06-17",{"date":41,"type":42},"2026-06-18","ACTUAL",{"date":44,"type":42},"2026-06-16",{"date":46,"type":21},"2027-06",{"name":48,"class":49},"Hospices Civils de Lyon","OTHER",12,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100621387","repetitive-transcranial-magnetic-stimulation-combined-with-language-training-for-language-disorders-in-children-with-global-developmental-delay-100621387","NCT07369960","Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Global Developmental Delay","Randomized Controlled Study for Repetitive Transcranial Magnetic Stimulation Combined With Language Training in Children With Language Disorders in Children With Global Developmental Delay","Inclusion criteria\n\n1. Children aged 2-5 years old, regardless of gender.\n2. Meet the diagnostic definition of GDD in China's Diagnostic Guidelines for Global Developmental Delay (2024), confirmed by Gesell Developmental Schedules (GDS). Language domain Developmental Quotient (DQ) ≤ 75. A DQ ≤ 75 is found in at least one of the four developmental domains: gross motor, fine motor, adaptive behavior, and personal-social conduct. Mild-moderate GDD is selected for the study.\n3. The presence of significant language developmental delay, the language ability is significantly lower than children of the same age and the same intellectual level, confirmed by the standardized scale of Sign-Significate Relations (S-S) assessment.\n4. The child is able to cooperate with the completion of rTMS treatment and language assessment and has no serious behavioral problems.\n5. Written informed consent obtained from the child's legal guardian. Exclusion Criteria\n\n1\\. History of epilepsy or convulsive seizures. 2. Having metal implants in the skull (e.g. aneurysm clips, metal stents, etc.) and electronic devices such as pacemakers and cochlear implants in the body.\n\n3\\. Other serious neurological conditions that may affect language function (e.g., cerebral palsy, progressive neurological disorders, etc.).\n\n4\\. Have a diagnosis of ASD. 5. Have a severe hearing or visual impairment. 6. Participation in other clinical trials that may affect speech function. 7. Skin lesions or infection at the scalp treatment site. 8. The fontanelle has not yet closed. 9. Previous rTMS treatment in the last 3 months. 10. Developmental quotient \\\u003C 40 in any developmental domains; other circumstances that prevented cooperation with the study.","2 Years","5 Years",{"count":61,"type":21},50,"INTERVENTIONAL",[64],"NA","This study explores a safe and effective new approach to improve language function in children with Global Developmental Delay (GDD). Conducted at Xiangxi Autonomous Prefecture People's Hospital, the study will recruit approximately 50 children aged 2 to 5 years. Participants will be randomly assigned to one of two groups: one receiving personalized language training combined with non-invasive, painless repetitive Transcranial Magnetic Stimulation (rTMS) to activate language regions of the brain, and a control group receiving personalized training for comparative analysis. The study spans one month, including a two-week intervention period followed by a two-week follow-up to evaluate the efficacy and sustainability of the combined therapy. This study has been rigorously reviewed and approved by the hospital's Ethics Committee.",[67,68,69,70],"Developmental Delay Disorder","Repetitive Transcranial Magnetic Stimulation (rTMS)","Global Developmental Delay","Language Disorders in Children","2026-05-28",{"date":73,"type":42},"2026-06-02",{"date":75,"type":21},"2026-05-27",{"date":77,"type":21},"2026-12-31",{"name":79,"class":49},"Xiangya Hospital of Central South University",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":62,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":80},"100639613","mindful-movement-and-game-based-training-in-developmental-delay-100639613","NCT07575165","Mindful Movement And GAME BASED Training In Developmental Delay","Comparative Effects Of Mindful Movement And Game Based Training On Motor Skills, Balance And Gait In Children With Developmental Delay","MINDGAME","Inclusion Criteria:\n\n* Children age 9-11 years\n* Both male and female\n* Children diagnosed with developmental delay\n* Mini mental state examination\n* Participants who are able to understand and follow the instruction\n* Bruininks-Oseretsky Test of Motor Proficiency (BOT-2): \\\u003C 25th percentile\n* Pediatric Berg Balance Scale (PBS) score of less than 45\n* Functional Reach Test (FRT): \\\u003C 6-7 inches\n* Observational Gait Scale (OGS): Likert-type scale 0 to 4\n* Edinburgh Visual Gait Score (EVGS): Scale 0 to 6\n\nExclusion Criteria:\n\n* Any cognitive impairment that limits understanding of instructions\n* Uncontrolled seizures or medical conditions that contraindicate therapy\n* Participation in other structured physiotherapy programs targeting motor skills, gait and balance\n* Children with other neurological diseases will be excluded","9 Years","11 Years",{"count":92,"type":21},36,[64],"Developmental delay in children is characterized by delayed acquisition of cognitive, motor, language, and social skills and is commonly associated with conditions such as cerebral palsy, autism spectrum disorder, and genetic disorders. Children with developmental delay frequently experience impairments in motor skills, balance, and gait, which negatively affect their functional independence and social participation. Addressing these motor deficits is essential to enhance their quality of life.\n\nMindful movement and game-based training are two therapeutic approaches that have shown potential in improving motor performance in this population. Mindful movement emphasizes slow, controlled movements, body awareness, emotional regulation, imaginative play, and biomechanical warm-up exercises to enhance motor control. In contrast, game-based training employs engaging and interactive activities to improve motor coordination, balance, strength, and social interaction.\n\nThis randomized clinical trial aims to compare the effects of mindful movement and game-based training in children with developmental delay. The study will be conducted at PSRD Hospital over a 10-month period and will include 36 children aged 9-11 years selected through non-probability convenience sampling. Participants will be randomly assigned to two groups: Group A will receive mindful movement therapy, and Group B will undergo game-based training. Outcomes will be assessed using validated tools, including the Bruininks-Oseretsky Test of Motor Proficiency (BOT-2), Pediatric Berg Balance Scale (PBS), Functional Reach Test (FRT), Observational Gait Scale (OGS), and Edinburgh Visual Gait Score (EVGS), to evaluate motor skills, balance, gait, and overall motor proficiency.",[27],[97],"Developmental Delay Mindful Movement Game-Based Training","NOT_YET_RECRUITING","2026-05-04",{"date":101,"type":42},"2026-05-08",{"date":103,"type":21},"2026-05",{"date":105,"type":21},"2026-08-25",{"name":107,"class":49},"Riphah International University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":62,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":80},"100631799","behavioral-parent-training-to-address-early-childhood-disruptive-behavior-using-the-helping-our-toddlers-developing-our-childrens-skills-hot-docs-program-and-the-developing-our-childrens-skills-kindergarten-5th-grade-docs-k-5-program-100631799","NCT07505381","Behavioral Parent Training to Address Early Childhood Disruptive Behavior Using the Helping Our Toddlers, Developing Our Children's Skills (HOT DOCS) Program and the Developing Our Children's Skills Kindergarten-5th Grade (DOCS K-5) Program","HOT DOCS and DOCS K-5","DOCS parenting","Inclusion Criteria:\n\n* caregiver or professional caring for child ages 0-12 years, or\n* caregiver or professional caring for a child enrolled in kindergarten-5th grade.\n* Must speak English or Spanish.\n\nExclusion Criteria:\n\n* Language other than English or Spanish.\n* Caregiver\u002Fprofessional under the age of 18.",true,"18 Years",{"count":119,"type":21},800,[64],"HOT DOCS and DOCS K-5 are group-delivered behavioral parent training interventions for caregivers of children ages 0-12 years.",[123,124,27,125],"Disruptive Behavior","Developmental Disability","Behavior Problem of Childhood","2026-04-23",{"date":128,"type":42},"2026-04-29",{"date":130,"type":42},"2018-10-02",{"date":132,"type":21},"2028-09-30",{"name":134,"class":49},"University of South Florida",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":146,"conditions":147,"keywords":170,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":80},"100630855","intensive-multimodal-neurorehabilitation-targeting-neuroplasticity-in-pediatric-neurodevelopmental-and-chromosomal-disorders-100630855","NCT07493096","Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders","Functional and Neurodevelopmental Outcomes Following Intensive Multimodal Neurorehabilitation in Pediatric Patients With Neurodevelopmental Disorders, Including Chromosomal Abnormalities","GEN-HOPE","Inclusion Criteria:\n\n* Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.\n* Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:\n\n  * cerebral palsy\n  * autism spectrum disorder\n  * developmental delay\n  * hypoxic ischemic encephalopathy (HIE)\n  * traumatic brain injury\n  * sensory processing disorder\n  * chromosomal or genetic abnormalities\n  * Demonstrate functional impairments in one or more neurodevelopmental domains, including:\n* motor coordination or motor planning\n* sensory processing\n* attention or executive functioning\n* oculomotor or visual processing\n* communication\n* emotional or behavioral regulation\n* activities of daily living\n* Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day\u002F 5 days per week\n\n  * Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.\n  * Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable.\n\nExclusion Criteria:\n\n* Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.\n* Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.\n* Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.\n* Inability to attend or complete the full two-week intensive program.\n* Lack of sufficient baseline or post-intervention data to assess change in functional performance.\n* Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.","12 Years",{"count":145,"type":21},100,"This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.\n\nParticipants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.\n\nThe purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.\n\nThis study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.",[148,149,150,27,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169],"Neurodevelopmental Disorders","Neurodevelopmental Disorders (NDD)","Neurodevelopmental Disorders and Developmental Abnormalities","Cerebral Palsy (CP)","Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment","Cerebral Palsy Infantile","Cerebral Palsy Spastic Hemiplegic","Cerebral Palsy, Dyskinetic","Autism Spectrum Disorder","Autism Spectrum Disorder (ASD","Hypoxic Ischemic Encephalopathy","Hypoxic Ischemic Encephalopathy (HIE)","Traumatic Brain Injury (TBI)","Sensory Processing Disorder","Chromosomal Abnormalities","Genetic Disorders","Down Syndrome (Trisomy 21)","Fragile X Syndrome (FXS)","RETT Syndrome With Proven MECP2 Mutation","Williams Syndrome","22q11.2 Deletion Syndrome","Sensorimotor Integration",[171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,148,189,190,191,192,193,194],"Photobiomodulation","Low-Level Laser Therapy","Vibration Therapy","Tactile Stimulation","Cognitive Training","Behavioral Therapy","Intensive Therapy","Pediatric Neurorehabilitation","Multimodal Therapy","Neuroplasticity","Sensory Integration","Reflex Integration","Motor Planning","Executive Function","Emotional Regulation","Functional Outcomes","Activities of Daily Living","High Frequency Therapy","Rehabilitation","Child Development Disorders","Occupational Therapy","Physical Therapy Modalities","Early Intervention","Cognitive Therapy","2026-03-19",{"date":197,"type":42},"2026-03-25",{"date":199,"type":42},"2026-03-01",{"date":201,"type":21},"2036-12-30",{"name":203,"class":49},"Healing Hope International",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":116,"sex":17,"minAge":4,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":213,"conditions":214,"keywords":223,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":80},"100618256","investigating-phenotypic-epigenetic-and-neurogenetic-traits-in-rare-and-ultra-rare-neurodevelopmental-disorders-project-penguin-100618256","NCT07329257","Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)","Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders","For those with a rare condition:\n\nInclusion Criteria:\n\n* Diagnosed or suspected neurogenetic disorder\n* Individuals 0-99\n\nExclusion Criteria:\n\n* Individuals unwilling or unable to complete visits with the study team.\n\nFor control parents\u002Fcaregivers of those with a rare condition:\n\nInclusion Criteria:\n\n* No history of a neurological disorder.\n* \\>18 years.\n* Legal caregiver of the patient diagnosed with a rare neurodevelopmental disorder.\n\nExclusion Criteria:\n\n* Individuals unwilling or unable to complete the visit with the study team.\n* Individuals who have a history of neurological disorders.\n* \\\u003C 18 years old\n\nFor all individuals who participate in the skin biopsy:\n\n* Individuals with disease that is known to be associated with poor wound healing.\n* Individuals with a history of allergic reaction to lidocaine.\n* Medical History of cellulitis, diabetes mellitus, poor extremity circulation, deep vein thrombosis, or a history of non-traumatic amputation.\n* Currently taking anticoagulation or have taken with last 6 months","99 Years",{"count":145,"type":21},"Rare genetic neurodevelopmental disorders, such as Syt-1 or Baker Gordon Syndrome (BAGOS) arise from mutations in genes essential for brain development and function, often disrupting neurotransmission and neuronal connectivity. These conditions present with a wide range of symptoms including developmental delays, seizures, motor and behavioral challenges, and vary widely in severity. These disorders are complex, and they remain poorly understood and lack effective treatments.\n\nNatural history and clinical genetic studies are crucial for mapping how these disorders progress, improving diagnostic accuracy, and guiding therapy development. A major focus is identifying reliable biomarkers (genetic, imaging, and physiological) to track disease severity and support clinical trials. This study will securely collect and analyze data to better understand disease impact, develop patient-derived model systems, and build resources to support future treatments.",[215,216,217,218,219,220,221,222,27],"Baker Gordon Syndrome","Rare Neurodevelopmental Conditions","Rare Neurogenetic Conditions","Syt-1 Disorder","Epilepsy","Seizure","Genetic Mutations","Autism in Children",[215,224,225,226,227,228,229,230,231],"BAGOS","Rare Conditions","Rare","Neurogenetic","Neurodevelopmental","Ultra-rare","Genetic mutation","Autism","2025-12-28",{"date":234,"type":42},"2026-01-09",{"date":236,"type":42},"2025-12-04",{"date":238,"type":21},"2028-12",{"name":240,"class":49},"University of Missouri-Columbia",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":62,"phases":250,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":80},"100582235","early-phase-1-clinical-trial-of-the-dual-vector-base-editor-for-the-treatment-of-the-chd3-r1025w-mutation-100582235","NCT06860672","Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation","Safety, Tolerability and Preliminary Efficacy Study of a Single Intrathecal Injection of the Dual Vector AAV-CHD3-R1025W Base Editor for the Treatment of Developmental Disorders Caused by the R1025W Mutation in the CHD3 Gene","Inclusion Criteria:\n\n* Clinical diagnosis of Snijders Blok-Campeau syndrome\n* Heterozygous mutation of c.3073C\\>T, p.(Arg1025Trp) in the CHD3 gene\n* Normal liver, heart and immune function\n* Normal coagulation and platelet counts\n\nExclusion Criteria:\n\n* Brain tumor or intracranial space-occupying lesion\n* Contraindications to administration of lumbar puncture or sheath injection administration\n* Persistent status epilepticus or recurrent epileptic control instability\n* Presence of unstable systemic disease including active bacterial, fungal or HIV, hepatitis A, hepatitis B infection\n* Serum anti-AAV neutralizing antibody titer \\>1:50 (ELISA immunoassay)\n* Treatment with immunological agents other than protocol-specified prophylaxis within 3 months\n* Prior gene therapy\n* Participation in another clinical trial, or treatment with another investigational product within 30 days or 5 half-lives\n* Known allergy to any investigational product","10 Years",{"count":80,"type":21},[251],"EARLY_PHASE1","To evaluate the safety, tolerability and preliminary efficacy study of a single intrathecal injection of the dual vector AAV-CHD3-R1025W base editor for the treatment of developmental disorders caused by the R1025W mutation in the CHD3 gene",[67,254,255],"Intellectual Disability","Rare Diseases","2025-03-05",{"date":258,"type":42},"2025-03-06",{"date":260,"type":42},"2025-02-19",{"date":262,"type":21},"2025-09",{"name":264,"class":49},"Yongguo Yu",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":116,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":62,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":80},"100564137","early-phase-1-promoting-playfulness-100564137","NCT06625255","Promoting Playfulness","Promoting Playfulness: Tier 1 Strength-based Parent Education Program to Promote Child and Family Resilience","Inclusion Criteria:\n\n* Parent of a child aged 2 to 5 with no major disability (sensory, intellectual disability, neuromuscular disability).\n* Can commit to participating in two online sessions;\n* Has a device with a stable internet connection; and\n* Communicates with high school-level English.\n\nExclusion Criteria:\n\n• Parents with children who have severe behavioral or sensory issues.",{"count":273,"type":21},40,[251],"Health inequalities, social isolation, and family adversity impact a child's development. Play is the context for child development in all areas. A parent's ability to support children at play while being playful contributes to their psychological adjustment. The proposed tier 1, strengths-based educational program for parents of children aged 2 to 5 years with and without disabilities combines elements of a play-based approach and tips on effective parenting to support children's development by equipping parents with knowledge and empowering them to become change agents in their children's lives.",[27],[278,279,280],"play","playfulness","parent education","2024-10-02",{"date":283,"type":42},"2024-10-04",{"date":285,"type":42},"2024-09-16",{"date":287,"type":21},"2026-10-01",{"name":289,"class":49},"Florida Gulf Coast University"]